Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition

  • Autoimmune Disorder
  • Multiple Sclerosis (MS)
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
  • Arganda del Rey
  • Barcelona
  • Castelló de la Plana
  • Córdoba
  • Girona
  • Lleida
  • Madrid
  • Móstoles
  • Pozuelo de Alarcón
  • San Cristóbal de La Laguna
  • Sant Joan Despí
  • Santander
  • València
  • Vigo
Trial Identifier:

NCT02598167 ML29715

      Show trial locations

      The source of the below information is public registry websites such as,,, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to and/or and/or

      The below information is taken directly from public registry websites such as,,, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This multi-center non-interventional, observational, cross-sectional study in adult participants with relapsing remitting multiple sclerosis (RRMS) will evaluate the participants' preferences for disease modifying treatments (DMT) in routine clinical practice.

      Hoffmann-La Roche Sponsor
      NCT02598167,ML29715 Trial Identifier
      Multiple Sclerosis, Relapsing-Remitting Condition
      Official Title

      Assessing Patients Preferences Towards Disease-modifying Therapeutic Options in Relapsing Remitting Multiple Sclerosis

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participants aged greater than or equal to (>/=) 18 years
      • Participants who have a diagnosis of RRMS as documented in their medical records
      • Participants who have been prescribed a DMT for at least 3 months
      • Participants who have an expanded disability status scale (EDSS) score of 1-6 points
      Exclusion Criteria
      • Participants with any personal or medical condition that in opinion of the investigator would interfere with or make impossible proper participation in the study

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now